Therapeutic potential of neurogenesis and melatonin regulation in Alzheimer's disease

Mazel Mihardja, Jaydeep Roy, Kan Yin Wong, Luca Aquili, Boon Chin Heng, Ying Shing Chan, Man Lung Fung, Lee Wei Lim

    Research output: Contribution to journalReview articlepeer-review


    Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by the hallmark pathologies of amyloid-beta plaques and neurofibrillary tangles. Symptoms of this devastating disease include behavioral changes and deterioration of higher cognitive functions. Impairment of neurogenesis has also been shown to occur in AD, which adversely impacts new neuronal cell growth, differentiation, and survival. This impairment possibly results from the cumulative effects of the various pathologies of AD. Preclinical studies have suggested that the administration of melatonin-the pineal hormone primarily responsible for the regulation of the circadian rhythm-targets the effects of AD pathologies and improves cognitive impairment. It is postulated that by mitigating the effect of these pathologies, melatonin can also rescue neurogenesis impairment. This review aims to explore the effect of AD pathologies on neurogenesis, as well as the mechanisms by which melatonin is able to ameliorate AD pathologies to potentially promote neurogenesis.

    Original languageEnglish
    Pages (from-to)43-62
    Number of pages20
    JournalAnnals of the New York Academy of Sciences
    Issue number1
    Early online date22 Jul 2020
    Publication statusPublished - 1 Oct 2020


    Dive into the research topics of 'Therapeutic potential of neurogenesis and melatonin regulation in Alzheimer's disease'. Together they form a unique fingerprint.

    Cite this